EyePod

In this second of an exclusive three-part Ophthalmology Times EyePod podcast series on innovation, we continue our discussion with Jibran Sharieff, MD, and Brandon Kingrey, MD, who are residents at the Dean McGee Eye Institute (DMEI) in Oklahoma City, Oklahoma. They recently won second place at the Eyecelerator competition held before this fall’s American Academy of Ophthalmology conference in Chicago, receiving a $15,000 prize—the first such prize awarded to residents—for their development of a smartphone device designed to take fundus images. This innovative tool aims to advance ophthalmic imaging accessibility. 

The device in development leverages the built-in hardware of iPhones to capture fundus images without requiring batteries or expensive optics, making it highly affordable and portable. Designed for ease of use, it surpasses traditional fundus cameras and direct ophthalmoscopes in cost-effectiveness and accessibility, enabling broader use among healthcare providers. Join us as Sharieff and Kingrey share insights into their project and their journey as young innovators in eye care.

In this first of an exclusive three-part Ophthalmology Times EyePod podcast series on innovation, we meet Jibran Sharieff, MD, and Brandon Kingrey, MD, who are residents at the Dean McGee Eye Institute (DMEI) in Oklahoma City, Oklahoma. They recently won second place at the Eyecelerator competition held prior to this month's American Academy of Ophthalmology conference in Chicago, receiving a $15,000 prize—the first such prize awarded to residents—for their development of a smartphone device designed to take fundus images. This innovative tool aims to advance ophthalmic imaging accessibility. Join us as Sharieff and Kingrey share insights into their project and their journey as young innovators in eye care.

Take a look at a review of the highlights from Ophthalmology Times during the week of September 29, 2024. 

Peter J. McDonnell, MD, and Laura M. Periman, MD, discuss how artificial intelligence (AI) is transforming ophthalmology, especially in ocular surface disease. Dr. Periman highlights the potential of AI to streamline eye health screening and documentation, enabling ophthalmologists to focus on patients who require treatment. They emphasize how AI can enhance clinical efficiency, improve patient outcomes, and assist in making more precise treatment decisions. Dr. McDonnell adds that AI will allow ophthalmologists to have a much more productive and satisfying day in the clinic and operating room. Both believe AI will help advance the field and improve patient care globally.

Take a look at a review of the highlights from Ophthalmology Times during the week of September 29, 2024. 

Take a look at a review of the highlights from Ophthalmology Times during the week of September 22, 2024. 

Ehsan Sadri, MD, FACS, of Visionary Eye Institute in Newport Beach, California, sat down with Professor Emeritus Colin R. Green, PhD, DSc, Department of Ophthalmology, Faculty of Medical and Health Sciences, University of Auckland, in Auckland, New Zealand, to learn more about a novel therapy in development for the treatment of keratoconus and other corneal ectasias.

Green outlines the status of the research, involving a unique combination of transforming growth factor beta-3 and dexamethasone, and the setup for a proof-of-concept study (via TheiaNova, a spin-out early-stage company of the University of Auckland).

Green also offers career advice for vision scientists and entrepreneurs, advising that making the transition from basic research to research translation is challenging and that having an application in mind is crucial. He emphasizes the importance of persevering through the highs and lows of research and development, highlighting the long-term benefits and sense of achievement.

Take a look at a review of the highlights from Ophthalmology Times during the week of September 15, 2024. 

X-linked retinitis pigmentosa (XLRP) is a progressive disease that is more severe than other forms of RP. Affected male patients typically inherit a pathogenic variant of the RPGR gene on the X chromosome. In this podcast, an expert panel discusses diagnosing XLRP and provides an overview of clinical trials of gene therapies for XLRP. 

Thyroid eye disease is a condition frequently associated with Graves disease that involves both acute and chronic inflammation of the orbit. Patients may experience ocular discomfort, appearance changes, and vision loss. In this podcast, an expert panel discusses diagnosing TED and providing appropriate pharmacologic and surgical treatments.